Literature DB >> 20510681

Vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (ALL).

Caroline Demacq1, Vivian B Vasconcellos, Tatiane C Izidoro-Toledo, Vanessa da Silva Silveira, Renata Canalle, Rosane Gomes de Paula Queiroz, Luiz Gonzaga Tone, Jose E Tanus-Santos.   

Abstract

BACKGROUND: Angiogenesis has been shown as an important process in hematological malignancies. It consists in endothelial proliferation, migration, and tube formation following pro-angiogenic factors releasing, specially the vascular endothelial growth factor (VEGF), which angiogenic effect seems to be dependent on nitric oxide (NO). We examined the association among functional polymorphisms in these two angiogenesis related genes: VEGF (-2578C>A, -1154G>A, and -634G>C) and NOS3 (-786T>C, intron 4 b>a, and Glu298Asp) with prognosis of childhood acute lymphoblastic leukemia (ALL).
METHODS: The genotypes were determined and haplotypes estimated in 105 ALL patients that were divided in 2 groups: high risk (HR) and low risk of relapse (LR) patients. In addition, event-free survival curves according to genotypes were assessed.
RESULTS: The group HR compared to the LR showed a higher frequency of the alleles -2578C and -634C and the haplotype CGC for VEGF (0.72 vs. 0.51, p<0.008; 0.47 vs. 0.26, p<0.008; and 42.1 vs. 14.5, p<0.006; respectively) and a lower frequency of the haplotype CbGlu (0.4 vs. 8.8,p<0.006), for NOS3.
CONCLUSION: Polymorphisms of VEGF and NOS3 genes are associated with high risk of relapse, therefore may have a prognostic impact in childhood ALL. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20510681     DOI: 10.1016/j.cca.2010.05.025

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Molecular effects of genistein, as a potential anticancer agent, on CXCR-4 and VEGF pathway in acute lymphoblastic leukemia.

Authors:  Mohsen Shahmoradi; Fatemeh Banisharif-Dehkordi; Mahnoush Kouhihabibidehkordi; Mahdi GhatrehSamani; Mohammad-Saied Jami; Hedayatollah Shirzad; Batoul Pourgheysari
Journal:  Mol Biol Rep       Date:  2022-05-24       Impact factor: 2.742

2.  What role for angiogenesis in childhood acute lymphoblastic leukaemia?

Authors:  P Schneider; I Dubus; F Gouel; E Legrand; J P Vannier; M Vasse
Journal:  Adv Hematol       Date:  2011-11-09

3.  Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research.

Authors:  C Athena Aktipis; Virginia S Y Kwan; Kathryn A Johnson; Steven L Neuberg; Carlo C Maley
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

4.  Analysis of the expression levels of survivin and VEGF in patients with acute lymphoblastic leukemia.

Authors:  Man Yang; Yongqiang Liu; Shufang Lu; Zhifen Wang; Ran Wang; Youmei Zi; Jingdong Li
Journal:  Exp Ther Med       Date:  2012-10-26       Impact factor: 2.447

5.  Deciphering the Active Compounds and Mechanisms of Qixuehe Capsule on Qi Stagnation and Blood Stasis Syndrome: A Network Pharmacology Study.

Authors:  Yu-Xi Huang; Ding-Qiao Xu; Shi-Jun Yue; Yan-Yan Chen; Hui-Juan Tao; Rui-Jia Fu; Li-Ming Xing; Taiyi Wang; Yu-Ling Ma; Bao-An Wang; Yu-Ping Tang; Jin-Ao Duan
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-27       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.